EUVIMEDObjevte EUVIMED
Crossref

Creation of an in vitro model of GM1 gangliosidosis by CRISPR/Cas9 knocking‐out the GLB1 gene in SH‐SY5Y human neuronal cell line

Kamran Hosseini, Jafar Fallahi, Hadi Aligholi, Zahra Heidari, Elham Nadimi, Fatemeh Safari, Mohsen Sisakht, Amir Atapour, Sahar Khajeh, Seyed Mohammad Bagher Tabei, Vahid Razban

Cell Biochemistry and Function · 2024

DOI: 10.1002/cbf.4102 ↗

At a glance

Journal article in Cell Biochemistry and Function, 2024. Written by Kamran Hosseini and 10 co-authors. Institution: Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. Major MEDLINE topics: Gangliosidosis, GM1, CRISPR-Cas Systems. Cited 1 times so far (Crossref); 41 references. Funded by: Shiraz University of Medical Sciences.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

GM1 gangliosidosis is one type of hereditary error of metabolism that occurs due to the absence or reduction of β‐galactosidase enzyme content in the lysosome of cells, including neurons. In vitro, the use of neural cell lines could facilitate the study of this disease. By creating a cell model of GM1 gangliosidosis on the SH‐SY5Y human nerve cell line, it is possible to understand the main role of this enzyme in breaking down lipid substrate and other pathophysiologic phenomena this disease. To knock‐out the human GLB1 gene, guides targeting exons 14 and 16 of the GLB1 gene were designed using the CRISPOR and CHOP‐CHOP websites, and high‐efficiency guides were selected for cloning in the PX458 vector. After confirming the cloning, the vectors were transformed into DH5α bacteria and then the target vector was extracted and transfected into human nerve cells (SH‐SY5Y cell line) by electroporation. After 48 h, GFP + cells were sorted using the FACS technique and homozygous (compound heterozygous) single cells were isolated using the serial dilution method and sequencing was done to confirm them. Finally, gap PCR tests, X‐gal and Periodic acid‐Schiff (PAS) staining, and qPCR were used to confirm the knock‐out of the human GLB1 gene. Additionally, RNA sequencing data analysis from existing data of the Gene Expression Omnibus (GEO) was used to find the correlation of GLB1 with other genes, and then the top correlated genes were tested for further evaluation of knock‐out effects. The nonviral introduction of two guides targeting exons 14 and 16 of the GLB1 gene into SH‐SY5Y cells led to the deletion of a large fragment with a size of 4.62 kb. In contrast to the non‐transfected cell, X‐gal staining resulted in no blue color in GLB1 gene knock‐out cells indicating the absence of β‐galactosidase enzyme activity in these cells. Real‐time PCR (qPCR) results confirmed the RNA‐Seq analysis outcomes on the GEO data set and following the GLB1 gene knock‐out, the expression of its downstream genes, NEU1 and CTSA , has been decreased. It has been also shown that the downregulation of GLB1 ‐ NEU1 ‐ CTSA complex gene was involved in suppressed proliferation and invasion ability of knock‐out cells. This study proved that using dual guide RNA can be used as a simple and efficient tool for targeting the GLB1 gene in nerve cells and the knockout SH‐SY5Y cells can be used as a model investigation of basic and therapeutic surveys for GM1 gangliosidosis disease.

Subjects

MeSH terms (MEDLINE)

Gangliosidosis, GM1CRISPR-Cas SystemsHumansbeta-GalactosidaseNeuronsGene Knockout TechniquesModels, Biological

Author keywords

CRISPR/Cas9GLB1 geneGM1 gangliosidosisSH‐SY5Y cell linecell modelknock‐out

Substances

GLB1 protein, humanbeta-Galactosidase

Authors and institutions

  • Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Bone and Joint Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Medical Genetics, School of Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

  • Shiraz University of Medical Sciences

Cite

APA

Hosseini, K., Fallahi, J., Aligholi, H., Heidari, Z., Nadimi, E., Safari, F., Sisakht, M., Atapour, A., Khajeh, S., Tabei, S. M. B., & Razban, V. (2024). Creation of an in vitro model of GM1 gangliosidosis by CRISPR/Cas9 knocking‐out the GLB1 gene in SH‐SY5Y human neuronal cell line. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.4102

Vancouver

Hosseini K, Fallahi J, Aligholi H, Heidari Z, Nadimi E, Safari F, et al. Creation of an in vitro model of GM1 gangliosidosis by CRISPR/Cas9 knocking‐out the GLB1 gene in SH‐SY5Y human neuronal cell line. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.4102

BibTeX
@article{Hosseini2024,
  author = {Hosseini, Kamran and Fallahi, Jafar and Aligholi, Hadi and Heidari, Zahra and Nadimi, Elham and Safari, Fatemeh and Sisakht, Mohsen and Atapour, Amir and Khajeh, Sahar and Tabei, Seyed Mohammad Bagher and Razban, Vahid},
  title = {Creation of an in vitro model of GM1 gangliosidosis by CRISPR/Cas9 knocking‐out the GLB1 gene in SH‐SY5Y human neuronal cell line},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  doi = {10.1002/cbf.4102}
}
Start for free →